Commonwealth Equity Services’s Cytosorbents Corp CTSO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-10,129
Closed -$13K 3727
2022
Q3
$13K Sell
10,129
-885
-8% -$1.73K ﹤0.01% 3604
2022
Q2
$24K Buy
11,014
+45
+0.4% +$103 ﹤0.01% 3554
2022
Q1
$34K Sell
10,969
-1,054
-9% -$3.77K ﹤0.01% 3617
2021
Q4
$50K Sell
12,023
-4,636
-28% -$26K ﹤0.01% 3531
2021
Q3
$135K Sell
16,659
-2,264
-12% -$18.4K ﹤0.01% 3364
2021
Q2
$142K Buy
18,923
+1,738
+10% +$14.6K ﹤0.01% 3346
2021
Q1
$149K Hold
17,185
﹤0.01% 3203
2020
Q4
$136K Hold
17,185
﹤0.01% 3018
2020
Q3
$137K Buy
17,185
+1,400
+9% +$12.6K ﹤0.01% 2818
2020
Q2
$156K Sell
15,785
-200
-1% -$1.84K ﹤0.01% 2684
2020
Q1
$123K Hold
15,985
﹤0.01% 2534
2019
Q4
$61K Hold
15,985
﹤0.01% 2786
2019
Q3
$80K Sell
15,985
-2,000
-11% -$11.6K ﹤0.01% 2705
2019
Q2
$118K Buy
17,985
+300
+2% +$2.06K ﹤0.01% 2617
2019
Q1
$133K Sell
17,685
-750
-4% -$5.84K ﹤0.01% 2553
2018
Q4
$148K Sell
18,435
-200
-1% -$1.99K ﹤0.01% 2414
2018
Q3
$240K Buy
18,635
+1,200
+7% +$15K ﹤0.01% 2360
2018
Q2
$199K Buy
+17,435
New +$165K ﹤0.01% 2466

Other funds holding CTSO

Commonwealth Equity Services's CTSO Position: Q4 2022 in Review

Commonwealth Equity Services sold out of Cytosorbents Corp (CTSO) in Q4 2022, closing a stake of 10,129 shares — an estimated $13K sold.

Commonwealth Equity Services first reported a position in CTSO in Q2 2018 and held it in 18 quarters. The position peaked at $240K in Q3 2018. 53 funds tracked by Wall St. Rank hold CTSO as of Q4 2022.

  • Commonwealth Equity Services reported no remaining Cytosorbents Corp position as of Q4 2022 after selling out during the quarter.
  • Commonwealth Equity Services sold 10,129 Cytosorbents Corp shares in Q4 2022, an estimated $13K.
  • Commonwealth Equity Services first reported a position in Cytosorbents Corp in Q2 2018 and held it in 18 quarters.
  • Commonwealth Equity Services's Cytosorbents Corp position peaked at $240K in Q3 2018.
  • 53 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2022.

Based on Commonwealth Equity Services's 13F filing for Q4 2022, filed 7 Feb 2023.